"VioQuest could be among the first companies to receive a priority review voucher," says Michael Becker, CEO of the New Jersey based biopharma company VioQuest Pharmaceuticals Inc.
The company plans to submit an NDA for sodium stibogluconate (Lenocta) at the end of 2008 or early in 2009...




